(Q39376791)

11 September 2017

title

Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib (English)

1 reference

11 September 2017

0 references

K Takeshita

7

0 references

author name string

H Mizuno

1

1 reference

11 September 2017

T Nakayama

2

1 reference

11 September 2017

Y Miyata

3

1 reference

11 September 2017

S Saito

4

1 reference

11 September 2017

S Nishiwaki

5

1 reference

11 September 2017

N Nakao

6

1 reference

11 September 2017

T Naoe

8

1 reference

11 September 2017

publication date

20 March 2012

1 reference

11 September 2017

1 reference

11 September 2017

volume

26

1 reference

11 September 2017

issue

10

1 reference

11 September 2017

page(s)

2269-2276

1 reference

Inflammation and cancer: back to Virchow?

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Preventive and therapeutic vaccines against Helicobacter pylori: current status and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Mast cells and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

The role of mast cells in tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-xL expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Determination of subcutaneous tumor size in athymic (nude) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

IL-1 Induces Vesicular Secretion of IL-6 without Degranulation from Human Mast Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Multistep tumorigenesis and the microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Mast cells are an essential component of human radiation proctitis and contribute to experimental colorectal damage in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

A quantitative study of mast cells in Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Fibrosis in Hodgkin and non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

A tense situation: forcing tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Proteasome inhibitors: antitumor effects and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Molecular mechanisms for the release of chemokines from human leukemic mast cell line (HMC)-1 cells activated by SCF and TNF-alpha: roles of ERK, p38 MAPK, and NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

The Bcl10-Malt1 complex segregates Fc epsilon RI-mediated nuclear factor kappa B activation and cytokine production from mast cell degranulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Proteasome inhibition as a new therapeutic principle in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

Risk factors for hepatocellular carcinoma among patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

inferred from DOI database lookup

7 January 2021

based on heuristic

Macrophages and their subpopulations following allogenic bone marrow transplantation for chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.81

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2012.81

1 reference

11 September 2017

1 reference